万达生物制药 VNDA 深 沪
已收盘 08-14 16:00:00 美东时间
5.22
+0.190
+3.78%
华盛通- 最 高5.28
- 今 开5.04
- 成交量 96.51万股
- 最 低 4.955
- 昨 收 5.03
- 总市值 3.16亿
- 52周最高 9.94
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 4.27
- 委 比 68.80%
- 总股本 6046.27万
- 历史最高 33.44
- 量 比 0.76
- 振 幅 6.46%
- 历史最低 2.92
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
08-10 18:23
Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (C...
07-08 04:33
Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4
05-27 19:11
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.
05-11 19:04
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Vanda Pharmaceuticals' NEREUS Now Commercially Available Throughout U.S. To Prevent Vomiting Induced By Motion In Adults
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults,
05-02 04:38
Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving glucagon-like
04-09 04:59
Vanda Announces Resignation of Senior Legal Executive
Vanda ( ($VNDA) ) has issued an update. On March 29, 2026, Vanda Pharmaceutical...
04-03 06:04
